These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26858332)

  • 21. Influence of an acidic beverage (Coca-Cola) on the pharmacokinetics of phenytoin in healthy rabbits.
    Kondal A; Garg SK
    Methods Find Exp Clin Pharmacol; 2003 Dec; 25(10):823-5. PubMed ID: 14735231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
    Catalán-Latorre A; Sureda M; Brugarolas-Masllorens A; Escudero-Ortiz V
    Ther Drug Monit; 2021 Aug; 43(4):447-450. PubMed ID: 33840795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of acidic beverage (Coca-Cola) on pharmacokinetics of ibuprofen in healthy rabbits.
    Kondal A; Garg SK
    Indian J Exp Biol; 2003 Nov; 41(11):1322-4. PubMed ID: 15332505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
    Samant TS; Dhuria S; Lu Y; Laisney M; Yang S; Grandeury A; Mueller-Zsigmondy M; Umehara K; Huth F; Miller M; Germa C; Elmeliegy M
    Clin Pharmacol Ther; 2018 Aug; 104(2):374-383. PubMed ID: 29134635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib and pantoprazole: a relevant interaction or not?
    Ter Heine R; Fanggiday JC; Lankheet NA; Beijnen JH; Van Der Westerlaken MM; Staaks GH; Malingré MM
    Br J Clin Pharmacol; 2010 Dec; 70(6):908-11. PubMed ID: 21175447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
    Spigel DR; Edelman MJ; O'Byrne K; Paz-Ares L; Mocci S; Phan S; Shames DS; Smith D; Yu W; Paton VE; Mok T
    J Clin Oncol; 2017 Feb; 35(4):412-420. PubMed ID: 27937096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data.
    Fotaki N; Klein S
    Mol Pharm; 2013 Nov; 10(11):4016-23. PubMed ID: 23947755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
    Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
    J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
    Katsuya Y; Fujiwara Y; Sunami K; Utsumi H; Goto Y; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Takashima Y; Osawa S; Ohe Y; Tamura T; Hamada A
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):125-32. PubMed ID: 25994853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of erlotinib in daily practice: a study on adherence and patients' experiences.
    Timmers L; Boons CC; Mangnus D; Moes JE; Swart EL; Boven E; Smit EF; Hugtenburg JG
    BMC Cancer; 2011 Jul; 11():284. PubMed ID: 21722354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of an acidic beverage (Coca-Cola) on the pharmacokinetics of carbamazepine in healthy volunteers.
    Malhotra S; Dixit RK; Garg SK
    Methods Find Exp Clin Pharmacol; 2002; 24(1):31-3. PubMed ID: 11980385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
    Hilton JF; Tu D; Seymour L; Shepherd FA; Bradbury PA
    Lung Cancer; 2013 Oct; 82(1):136-42. PubMed ID: 23910908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
    Zhou X; Tao H; Shi KH
    Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
    Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
    Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
    Sakamoto S; Sato K; Takita Y; Izumiya Y; Kumagai N; Sudo K; Hasegawa Y; Yokota H; Akamine Y; Okuda Y; Asano M; Takeda M; Sano M; Miura M; Nakayama K
    Invest New Drugs; 2020 Dec; 38(6):1687-1695. PubMed ID: 32436059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
    Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
    Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
    Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
    Masago K; Togashi Y; Fukudo M; Terada T; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
    Clin Lung Cancer; 2011 Sep; 12(5):307-12. PubMed ID: 21775215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.